CAMP4 Therapeutics Corporation announced the appointment of Michael MacLean as a Class III director, effective April 1, 2026. This decision was made during a Board of Directors meeting held on March 18, 2026. With this appointment, the Board will increase its size from eight to nine members. Mr. MacLean brings over 35 years of financial leadership experience in the biotechnology and life sciences sectors. He has held significant positions, including Chief Financial Officer at Avidity Biosciences, where he played a crucial role in the company's growth and its acquisition by Novartis. His extensive background in public company reporting, capital markets transactions, and corporate governance is expected to enhance the Board's capabilities. Additionally, Mr. MacLean will serve on both the Audit Committee and the Compensation Committee. In connection with his appointment, the Board approved an amendment to the Company’s non-employee director compensation policy, which will grant new directors an option to purchase 56,000 shares of common stock, vesting over three years. This strategic move is anticipated to positively influence the company's governance and operational execution, aligning with the interests of shareholders.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.